| oxaliplatin / Generic mfg. |
| Completed | 2b | 198 | US, Europe, RoW | Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) | Bayer, Amgen | Metastatic Colorectal Cancer | 01/11 | 02/12 | | |
|
| Terminated | 2b | 191 | Japan, US, Europe | sunitinib, Sutent, SU011248, mFOLFOX6, bevacizumab, Avastin | Pfizer | Colorectal Neoplasms | 07/11 | 07/11 | | |
NCT00004102: Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | NYU Langone Health, National Cancer Institute (NCI) | Colorectal Cancer | 11/01 | | | |
NCT00004127: Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach |
|
|
| Completed | 2 | 35 | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | University of Chicago, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 10/02 | 08/03 | | |
NCT00006015: Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 26 | US | trastuzumab, Herceptin, fluorouracil, 5-FU, leucovorin calcium, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer | 12/02 | 02/03 | | |
NCT00026299: Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer |
|
|
| Completed | 2 | 14 | US | ZD1839, gefitinib, Iressa ®, oxaliplatin, Eloxatin ® | University of Chicago, National Cancer Institute (NCI) | Colorectal Cancer | 12/02 | 02/05 | | |
NCT00004190: Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer |
|
|
| Completed | 2 | 59 | US, Canada | gemcitabine hydrochloride, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Pancreatic Cancer | 04/03 | 06/03 | | |
NCT00016198: Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | Prologue Research International | Colorectal Cancer | 04/03 | 12/10 | | |
NCT00017082: Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | oxaliplatin | Prologue Research International | Colorectal Cancer | 06/03 | 12/10 | | |
NCT00044343: GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin |
|
|
| Completed | 2 | 80 | US, Canada | lapatinib | GlaxoSmithKline | Colorectal Cancer | 10/03 | 10/03 | | |
NCT00065117: Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 180 | US | ZD6126, Placebo, 5-fluorouracil, leucovorin, oxaliplatin | AstraZeneca | Colorectal Neoplasms, Metastases, Neoplasm | 02/04 | 02/04 | | |
NCT00016952: Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 19 | US, Canada | fluorouracil, irinotecan hydrochloride, leucovorin calcium | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 04/04 | 10/09 | | |
NCT00005836: Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy |
|
|
| Completed | 2 | | US, Canada | oxaliplatin | Gynecologic Oncology Group, National Cancer Institute (NCI) | Ovarian Cancer, Primary Peritoneal Cavity Cancer | | 07/04 | | |
NCT00070265: Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer |
|
|
| Terminated | 2 | 80 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, capecitabine, CAPE, Ro 09-1978/000, Xeloda, therapeutic conventional surgery, laboratory biomarker analysis | National Cancer Institute (NCI) | Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 09/04 | | | |
NCT00040859: Oxaliplatin and Capecitabine in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer |
|
|
| Completed | 2 | 48 | US | capecitabine, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Esophageal Cancer, Gastric Cancer | 01/05 | 04/08 | | |
NCT00080951: Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 14 | US | fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 04/05 | 02/08 | | |
NCT00399750: TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 373 | US | oxaliplatin, fluoropyrimidine, bevacizumab | Sanofi | Colorectal Cancer | | 06/05 | | |
NCT00039208: Combination Chemotherapy in Treating Patients With Colorectal Cancer |
|
|
| Completed | 2 | | Europe | fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin | European Organisation for Research and Treatment of Cancer - EORTC | Colorectal Cancer | 08/05 | | | |
SAKK 41/04, NCT00227734: Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 74 | Europe | capecitabine and oxaliplatin + cetuximab, capecitabine and oxaliplatin | Swiss Group for Clinical Cancer Research | Colorectal Cancer | 10/05 | 02/06 | | |
NCT00003834: Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 44 | US, Canada | fluorouracil, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | 12/05 | 12/05 | | |
NCT00026234: Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver |
|
|
| Completed | 2 | 75 | US | floxuridine, 5-FUDR, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, capecitabine, CAPE, Ro 09-1978/000, Xeloda | National Cancer Institute (NCI), NSABP Foundation Inc | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 01/06 | | | |
NCT00052364: Oxaliplatin in Treating Patients With Liver Cancer |
|
|
| Completed | 2 | 32 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, laboratory biomarker analysis | National Cancer Institute (NCI) | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer | 01/06 | | | |
NCT00268333: Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 39 | Europe | fluorouracil, leucovorin calcium, oxaliplatin, neoadjuvant therapy | GERCOR - Multidisciplinary Oncology Cooperative Group | Colorectal Cancer | 01/06 | | | |
NCT00070434: S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum |
|
|
| Withdrawn | 2 | 0 | US | capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, radiation therapy, Pyridoxine | Southwest Oncology Group, National Cancer Institute (NCI) | Colorectal Cancer | 02/06 | | | |
NCT00091182: Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment |
|
|
| Completed | 2 | 180 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP | National Cancer Institute (NCI) | Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma, Childhood High-grade Cerebral Astrocytoma, Childhood Low-grade Cerebral Astrocytoma, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor, Childhood Teratoma, Recurrent Adrenocortical Carcinoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Colon Cancer, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Nasopharyngeal Cancer, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer | 02/06 | | | |
| Completed | 2 | 200 | US | ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen) | Mayo Clinic | Locally Advanced Unresectable or Stage IV Colorectal Cancer | 06/06 | 06/06 | | |
| Completed | 2 | 20 | RoW | Oxaliplatin | Sanofi | Stomach Neoplasms | 07/06 | 07/06 | | |
NCT00103298: Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, isolated perfusion, leucovorin calcium, melphalan, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | | 07/06 | | |
NCT00250822: Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter |
|
|
| Completed | 2 | 11 | US | Gemcitabine and Oxaliplatin | New Mexico Cancer Care Alliance | Liver Cancer | 07/06 | 07/06 | | |
NCT00123851: Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 32 | US | Tarceva (OSI-774), Capecitabine, Oxaliplatin | Dana-Farber Cancer Institute, Sanofi-Synthelabo, OSI Pharmaceuticals, Hoffmann-La Roche, Genentech, Inc., Massachusetts General Hospital, Beth Israel Deaconess Medical Center | Colorectal Cancer, Neoplasm Metastasis | 08/06 | 08/06 | | |
NCT00142467: Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma |
|
|
| Completed | 2 | 33 | US | Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Bevacizumab, Avastin | Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Genentech, Inc., Sanofi-Synthelabo, Eli Lilly and Company | Hepatocellular Carcinoma | 08/06 | 06/11 | | |
NCT02694718: A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer |
|
|
| Completed | 2 | 60 | Europe | Capecitabine, Xeloda, Ro09-1978, Oxaliplatin, Eloxatin | Hoffmann-La Roche, Sanofi-Synthélabo (Schweiz) AG | Rectal Cancer | 08/06 | 11/06 | | |
NCT00112528: Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer |
|
|
| Completed | 2 | 53 | US | bevacizumab, gemcitabine hydrochloride, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Pancreatic Cancer | 08/06 | 11/10 | | |
NCT00378066: Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer |
|
|
| Completed | 2 | 49 | RoW | Bevacizumab, Capecitabine, Oxaliplatin | Asan Medical Center | Metastatic Colorectal Cancer | 08/06 | 10/08 | | |
| Completed | 2 | 67 | Europe | oxaliplatin | Sanofi | Biliary Tract Neoplasms | 09/06 | 09/06 | | |
NCT00262808: GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer |
|
|
| Completed | 2 | 50 | US | sargramostim, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery, neoadjuvant therapy | University of Rochester | Colorectal Cancer | 09/06 | 09/06 | | |
NCT00276861: Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer |
|
|
| Terminated | 2 | 10 | US | gemcitabine hydrochloride, oxaliplatin | University of Miami | Colorectal Cancer | 09/06 | 05/08 | | |
NCT00025142: Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, gefitinib, leucovorin calcium, oxaliplatin | Stanford University, National Cancer Institute (NCI) | Colorectal Cancer | | 11/06 | | |
NCT00280618: Oxaliplatin in Unresectable Hepatocellular Carcinoma |
|
|
| Completed | 2 | | RoW | Oxaliplatin | Sanofi | Carcinoma, Hepatocellular | 11/06 | | | |
NCT00254137: Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 92 | Europe | capecitabine, irinotecan, oxaliplatin, cetuximab | Ludwig-Maximilians - University of Munich, Merck Sharp & Dohme LLC, Sanofi, Pfizer, Hoffmann-La Roche | Metastatic Colorectal Cancer | | 11/06 | | |
NCT00311610: Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 30 | US | SN-38 liposome | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 01/07 | 06/10 | | |
NCT00256269: Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma |
|
|
| Terminated | 2 | 4 | US | Oxaliplatin, Irinotecan | University of California, Irvine, Sanofi | Esophageal Cancer, Gastroesophageal Cancer | 02/07 | 02/07 | | |
PROCTFUL, NCT00263029: Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer |
|
|
| Completed | 2 | 18 | RoW | Oxaliplatin, Capecitabine, Radiotherapy | Sanofi | Rectal Neoplasms | 03/07 | | | |
OPUS, NCT00125034: Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) |
|
|
| Completed | 2 | 344 | Europe, RoW | Cetuximab, Oxaliplatin | Merck KGaA, Darmstadt, Germany | Neoplasm Metastasis, Colorectal Cancer | 03/07 | 11/10 | | |
|
|
|
|
|
NCT00096070: Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer |
|
|
| Completed | 2 | 50 | US | radiation therapy, irradiation, radiotherapy, therapy, radiation, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar | National Cancer Institute (NCI) | Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer | 04/07 | | | |
NCT00118105: S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, Avastin, NSC-704865, capecitabine, Xeloda, NSC-712807, oxaliplatin, NSC-266046, conventional surgery | Southwest Oncology Group, National Cancer Institute (NCI), Eastern Cooperative Oncology Group | Colorectal Cancer, Metastatic Cancer | 04/07 | 04/07 | | |
NCT00083616: Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy |
|
|
| Completed | 2 | 185 | US | Panitumumab, ABX-EGF, Vectibix | Amgen | Colorectal Cancer, Metastatic Cancer | 05/07 | 12/08 | | |
NCT00016978: Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan |
|
|
| Completed | 2 | 40 | US, Canada | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer | 06/07 | | | |
NCT00043004: Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 119 | Europe, RoW | bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiofrequency ablation | European Organisation for Research and Treatment of Cancer - EORTC, Arbeitsgruppe Lebermetastasen und Tumoren, Institute of Cancer Research, United Kingdom | Colorectal Cancer, Metastatic Cancer | 06/07 | | | |
NCT00215982: Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 24 | US | capecitabine, XELODA™, Oxaliplatin, E LOXATIN™, Irinotecan, CAMPTOSAR™ | H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG | Colorectal Cancer | 07/07 | 07/07 | | |
NCT00094965: Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function |
|
|
| Completed | 2 | 43 | US | Oxaliplatin (SR96669) | Sanofi | Gastrointestinal Cancer | 08/07 | 08/07 | | |
NCT00056030: Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 73 | US | cetuximab, fluorouracil, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | 10/07 | | | |
| Completed | 2 | 150 | Europe, RoW | Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan, FOLFOX 6, FOLFIRI | Central European Cooperative Oncology Group | Metastatic Colorectal Cancer | | 10/07 | | |
NCT00192075: A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 84 | US | Gemcitabine, Gemzar, avastin, 5FU/folinic acid, oxaliplatin | Eli Lilly and Company | Colorectal Cancer | | 11/07 | | |
NCT00174616: CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision |
|
|
| Completed | 2 | 87 | Europe | Oxaliplatin, capecitabine, radiotherapy | Sanofi | Rectal Neoplasms | 11/07 | 11/07 | | |
| Completed | 2 | 215 | Canada, Europe | AZD2171, cediranib, RECENTIN™, 5-fluorouracil, 5-FU, Leucovorin, Oxaliplatin, Eloxatin®, Bevacizumab, Avastin® | AstraZeneca | Colorectal Cancer | 11/07 | 10/09 | | |
NCT00416494: Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer |
|
|
| Completed | 2 | 50 | US | bevacizumab, oxaliplatin, Capecitabine | Herbert Hurwitz, MD, National Cancer Institute (NCI) | Colorectal Cancer | 01/08 | 08/14 | | |
NCT02723253: Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer |
|
|
| Completed | 2 | 18 | Europe | Radiotherapy, Tom-OX, Tomudex ®, Eloxatin ® | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Rectal Neoplasms | 01/08 | 02/12 | | |
NCT00153998: Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM) |
|
|
| Completed | 2 | 135 | Europe | Cetuximab, Liver resection, Cetuximab and FOLFIRI, Cetuximab(C225, Erbitux®, Merck KGaA), Irinotecan (irinotecan HCl, CPT-11 or Campto®, Aventis), 5-Fluorouracil (5-FU), Folinic acid (FA, i.e. Leucovorin®, Wyeth), Cetuximab and FOLFOX, Oxaliplatin (L-OHP, Eloxatin®, Sanofi-Synthelabo) | Technische Universität Dresden | Colorectal Cancer, Liver Metastases | 03/08 | | | |
|
|
|
|
NCT00381862: Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX |
|
|
| Completed | 2 | 54 | US | aprepitant, Emend, MK-869, L-758,298, L-754,030, dexamethasone, fluorouracil, 5-FU, irinotecan hydrochloride, Trade names: Camptosar®, Other names: Camptothecin-11, CPT-11, leucovorin calcium, Generic Name: Leucovorin, Other Names: Citrovorum Factor, Folinic Acid, oxaliplatin, Trade Name: Eloxatin, palonosetron hydrochloride, Aloxi, quality-of-life assessment | OHSU Knight Cancer Institute, National Cancer Institute (NCI) | Colorectal Cancer, Nausea and Vomiting | 03/08 | 07/08 | | |
NCT00454116 / 2006-005023-42: A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients |
|
|
| Completed | 2 | 106 | US, Europe, RoW | Vandetanib, ZD6474, ZACTIMA™, FOLFIRI | Genzyme, a Sanofi Company | Colorectal Cancer | 03/08 | 11/09 | | |
NCT00500292 / 2006-005022-23: A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer |
|
|
| Completed | 2 | 109 | Europe, RoW | Vandetanib, AZ6474, ZACTIMA™, SAR390530, FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid | Genzyme, a Sanofi Company | Colorectal, Cancer | 03/08 | 11/16 | | |
NCT00408772: Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation | University of California, Davis, Sanofi | Colorectal Cancer, Metastatic Cancer | 04/08 | 04/08 | | |
NCT00253370: Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 44 | US | BAY 43-9006, Sorafenib (NSC724772), BAY 54-9085 (tosylate salt), docetaxel, Taxotere, RP 56976, NSC #628503, cisplatin, Cis-diaminedichloroplatinum, Cis-diaminedichloroplatinum (II), diaminedichloroplatinum, cis-platinum, platinum, Platinol, Platinol-AQ, DDP, CDDP, DACP, NSC 119875. | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer | 05/08 | 09/10 | | |
NCT01851941: A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer |
|
|
| Completed | 2 | 52 | RoW | mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin ) | Seoul National University Hospital | Advanced Gastric Cancer | 06/08 | | | |
NCT00354224: Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Stomach Cancer |
|
|
| Terminated | 2 | 10 | US | capecitabine, oxaliplatin | Medical University of South Carolina | Gastric Cancer | 08/08 | 08/08 | | |
NCT00447967: Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients |
|
|
| Completed | 2 | 110 | Europe | Irinotecan, CPT-11, Oxaliplatin, LoHP, Fluorouracil, 5-FU, Leucovorin, LV | Hellenic Oncology Research Group, University Hospital of Crete | Gastric Cancer | 09/08 | 09/08 | | |
NCT00259402: Oxaliplatin in Esophagus Cancer (Advanced) 1st Line |
|
|
| Completed | 2 | 41 | Europe | Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU) | Sanofi | Esophageal Neoplasms | 10/08 | 10/08 | | |
NCT00084617: Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma |
|
|
| Completed | 2 | 39 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, capecitabine, CAPE, Ro 09-1978/000, Xeloda | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer | 10/08 | 12/08 | | |
NCT00345696 / 2005-006171-12: 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. |
|
|
| Completed | 2 | 32 | Europe | Bevacizumab, Avastin, Capecitabine, Xeloda, Oxaliplatine, Eloxatin | Unidad Integral de Investigación en Oncología S.L., Hoffmann-La Roche | Metastatic Colorectal Cancer | 10/08 | 01/11 | | |
| Completed | 2 | 30 | Europe | Cetuximab + Gemcitabine + Oxaliplatin, Erbitux, GEMOX | Association of Research on the Biology of Liver Tumors | Unresectable, Locally Advanced, Metastatic | 10/08 | 10/09 | | |
NCT00755534: Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC |
|
|
| Terminated | 2 | 68 | Europe | Irinotecan, CPT-11, Campto, Capecitabine, Xeloda, Cetuximab, Erbitux, Oxaliplatin, Eloxatin, LoHP | Hellenic Oncology Research Group, University Hospital of Crete | Colorectal Cancer | 11/08 | 11/08 | | |
NCT00290615: Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 30 | US | bevacizumab, Avastin, cetuximab, capecitabine, oxaliplatin | Herbert Hurwitz, National Cancer Institute (NCI) | Colorectal Cancer | 01/09 | 01/11 | | |
| Completed | 2 | 136 | Europe | FOLFOX-4+cetuximab, FOLFOX-4 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Colorectal Cancer | 02/09 | 02/09 | | |
NCT01379482: Neo-adjuvant Chemo + Peritonectomy + Hyperthermic Intraperitoneal Chemo in Peritoneal Carcinomatosis From Gastric Cancer |
|
|
| Completed | 2 | 18 | Europe | Multimodal treatment, Irinotecan+Nordic FLv (6 pat.), EOX (6 pat.), FLOX (3 pat.), Docetaxel+Irinotecan+5-FU+LV (1 pat.), FOLFIRI (1 pat.), ECF (1 pat.), Cisplatin+doxorubicin (5 pat.)., Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.), 5-FU + i.v. LV (5 pat.), Paclitaxel (1 pat.) | Uppsala University | Peritoneal Carcinomatosis, Gastric Cancer | 03/09 | 03/09 | | |
NCT00361231: Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer |
|
|
| Completed | 2 | 35 | US | Bevacizumab, Avastin, Gemcitabine, Gemzar, Oxaliplatin, Eloxatin | Massachusetts General Hospital, Genentech, Inc., Sanofi, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute | Biliary Tract Cancer, Gallbladder Adenocarcinoma | 03/09 | 08/12 | | |
NCT00419159 / 2006-003255-20: Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy |
|
|
| Completed | 2 | 199 | US | Everolimus (RAD001), Afinitor, Zortress, Certican | Novartis Pharmaceuticals | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00786006: Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer |
|
|
| Completed | 2 | 61 | RoW | FOLFIRI.3, FOLFOX | Asan Medical Center | Metastatic Pancreatic Cancer | 03/09 | 09/09 | | |
NCT00642603: A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 41 | US | capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin, irinotecan | Hoffmann-La Roche | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00118755: A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 435 | US | capecitabine, Oxaliplatin, bevacizumab | Hoffmann-La Roche | Colorectal Cancer | 04/09 | | | |
NCT00335959: S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery |
|
|
| Terminated | 2 | 7 | US | capecitabine, Xeloda (NSC-712807), oxaliplatin, Eloxatin (NSC-266046), conventional surgery, gastrectomy, radiation therapy, RT | Southwest Oncology Group, National Cancer Institute (NCI) | Gastric Cancer | 04/09 | | | |
NCT00352755: A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis |
|
|
| Terminated | 2 | 18 | US | Surgical debulking with peritonectomy, Intraperitoneal 5FU, Fluorouracil, Efudex, FOLFOX, Oxaliplatin, Leucovorin, USAN | Washington University School of Medicine | Peritoneal Neoplasms | 04/09 | 04/09 | | |
FOIB, NCT01163396: First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 57 | Europe | Bevacizumab, Irinotecan, Oxaliplatin, 5-fluorouracil/leucovorin | Gruppo Oncologico del Nord-Ovest | Colorectal Cancer Metastatic | 04/09 | 04/10 | | |
NCT00531115 / 2006-007062-11: Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 28 | Europe | cetuximab 5mg/ml | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 04/09 | 04/09 | | |
NCT00338988: Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma |
|
|
| Completed | 2 | 44 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi-Synthelabo | Cancer of the Gallbladder, Cancer of the Biliary Tract | 05/09 | 05/09 | | |
NCT00386828: Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial |
|
|
| Completed | 2 | 43 | Canada | Bevacizumab: | British Columbia Cancer Agency | Advanced Colorectal Cancer | 05/09 | 05/09 | | |
NCT00711412: Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Esophageal or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 44 | US | Induction Therapy - Capecitabine, Induction Therapy - Oxaliplatin, Combination Therapy - Capecitabine, Combination Therapy - Oxaliplatin, Combination Therapy - Radiation, Evaluation for response and surgery | Northwestern University | Esophageal Cancer | 05/09 | 01/13 | | |
XELOX-A-DVS, NCT00159432: Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer |
|
|
| Completed | 2 | 63 | US | Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Capecitabine, Xeloda | University of Southern California, Hoffmann-La Roche, Genentech, Inc. | Colorectal Cancer | 06/09 | 03/13 | | |
|
NCT00508872: Folfox-B Study for Patients With Colorectal Liver Metastases |
|
|
| Terminated | 2 | 2 | US | 5-Fluorouracil, 5-FU, Adrucil, Efudex, Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Leucovorin, Citrovorum, Wellcovorin, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi | Colorectal Liver Metastases | 06/09 | 06/09 | | |
NCT00422864: A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer |
|
|
| Completed | 2 | 26 | RoW | oxaliplatin, fluorouracil, leucovorin, External beam radiotherapy | Peter MacCallum Cancer Centre, Australia | Rectal Cancer | 06/09 | 01/11 | | |
| Completed | 2 | 46 | Europe | NGR-hTNF | AGC Biologics S.p.A. | Colorectal Cancer (CRC) | 06/09 | 04/13 | | |
FUTURE, NCT00439517: Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. |
|
|
| Completed | 2 | 302 | Europe, RoW | UFOX + Cetuximab, FOLFOX4 + Cetuximab | Merck KGaA, Darmstadt, Germany | Previously Untreated Metastatic Colorectal Cancer | 06/09 | 05/12 | | |
|
|
NCT00568529: Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer |
|
|
| Suspended | 2 | 30 | RoW | Capecitabine and Oxaliplatin, XELOX(Xeloda and oxaliplatin combination) | Fudan University | Gastric Cancer | 06/09 | 02/10 | | |
MK-7454-003, NCT00551213: A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, ) |
|
|
| Completed | 2 | 67 | NA | Robatumumab, Irinotecan, Cetuximab, Capecitabine, FOLFOX, CAPEOX/XELOX, FOLFIRI | Merck Sharp & Dohme LLC | Colorectal Cancer | 06/09 | 06/09 | | |
TIROX2, NCT00512681: A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer |
|
|
| Completed | 2 | 44 | RoW | Irinotecan, Oxaliplatin, TS-1 | National Cancer Center, Korea | Stomach Neoplasms | 07/09 | 07/09 | | |
NCT00086996: S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction |
|
|
| Completed | 2 | 98 | US | fluorouracil, 5-FU, oxaliplatin, eloxatin, conventional surgery, radiation therapy | Southwest Oncology Group, National Cancer Institute (NCI) | Esophageal Cancer | 08/09 | 08/11 | | |
NCT00327119: Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer |
|
|
| Completed | 2 | 50 | Japan | ABX-EGF (panitumumab) | Amgen | Metastatic Colorectal Cancer | | | | |
NCT00296062: Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer |
|
|
| Terminated | 2 | 12 | US | bevacizumab, capecitabine, irinotecan hydrochloride, oxaliplatin | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 10/09 | 05/11 | | |
NCT00625183: Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma |
|
|
| Terminated | 2 | 5 | US | selenomethionine, capecitabine, oxaliplatin, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy | Roswell Park Cancer Institute, National Cancer Institute (NCI) | Colorectal Cancer | 10/09 | 12/09 | | |
NCT00831181: Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer |
|
|
| Completed | 2 | 27 | US | 5-FU, fluorouracil, Oxaliplatin, Eloxatin, leucovorin, Folinic Acid, mesorectal excision | Beth Israel Medical Center | Colorectal Cancer | 11/09 | 11/09 | | |
